Platform

Weir GM, MacDonald LD, Rajagopalan R, Sivko GS, Valderas MW, Rayner J, Berger BJ, Sammatur L, Stanford MM. Single dose of DPX-rPA, an enhanced-delivery anthrax vaccine formulation, protects against a lethal Bacillus anthracis spore inhalation challenge. npj Vaccines 4, 6, doi:10.1038/s41541-019-0102-z (2019).
https://www.nature.com/articles/s41541-019-0102-z

Weir GM, Hrytsenko O, Quinton T, Berinstein NL, Stanford MM, Mansour M. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide. J Immunother Cancer. 18;4:68, 2016
https://www.ncbi.nlm.nih.gov/pubmed/27777777

Weir GM, Hrytsenko O, Stanford MM, Berinstein NL, Karkada M, Liwski RS, Mansour M. Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response. OncoImmunology. 3;8:e953407, 2014
https://www.ncbi.nlm.nih.gov/pubmed/25960932

Karkada M, Weir GM, Quinton T, Sammatur L, MacDonald LD, Grant A, Liwski R, Juskevicius R, Sinnathamby G, Philip R, Mansour M. A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses. J Immunother. 33;3:250, 2010 https://www.ncbi.nlm.nih.gov/pubmed/20445345

Berinstein NL, Karkada M, Morse MA, Nemunaitis JL, Chatta G, Kaufman H, Odunsi K, Nigam R, Sammatur L, MacDonald LD, Weir GM, Stanford MM, Mansour M. First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. J Trans Med. 10;1:156, 2012 https://www.ncbi.nlm.nih.gov/pubmed/22862954

Berinstein NL, Karkada M, Oza AM, Odunsi K, Villella JA, Nemunaitis JJ, Morse MA, Pejovic T, Bentley J, Buyse M, Nigam R, Weir GM, MacDonald LD, Quinton T, Rajagopalan R, Sharp K, Penwell A, Sammatur L, Burzykowski T, Stanford MM, Mansour M. Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. OncoImmunology. 4;8:e1026529-1, 2015 https://www.ncbi.nlm.nih.gov/pubmed/26405584

Brewer KD, Lake K, Pelot N, Stanford MM, DeBay DR, Penwell A, Weir GM, Karkada M, Mansour M, Bowen CV. Clearance of depot vaccine SPIO-labeled antigen and substrate visualized using MRI. Vaccine. 32;51:6956, 2014 https://www.ncbi.nlm.nih.gov/pubmed/25444822

DeBay DR, Brewer KD, LeBlanc SA, Weir GM, Stanford MM, Mansour M, Bowen CV. Using MRI to evaluate and predict therapeutic success from depot-based cancer vaccines. Mol Ther-Methods & Clinical Development. 2:15048, 2015 https://www.ncbi.nlm.nih.gov/pubmed/26730395

MacDonald LD, Fuentes-Ortega A, Sammatur L, Mansour M. Efficacy of a single dose hepatitis B depot vaccine. Vaccine. 28;44:7143, 2010 https://www.ncbi.nlm.nih.gov/pubmed/20832491

Weir GM, Hrytsenko O, Quinton T, Berinstein NL, Stanford MM, Mansour M.  Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide. J Immunother Cancer. October, 2016 https://www.ncbi.nlm.nih.gov/pubmed/27777777

Berinstein NL, Karkada M, Oza AM, Odunsi K, Villella JA, Nemunaitis JJ, Morse MA, Pejovic T, Bentley J, Buyse M, Nigam R, Weir GM, MacDonald LD, Quinton T, Rajagopalan R, Sharp K, Penwell A, Sammatur L, Burzykowski T, Stanford MM, Mansour M. Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. OncoImmunology, May, 2015 https://www.ncbi.nlm.nih.gov/pubmed/26405584

Weir GM, Hrytsenko O, Stanford MM, Berinstein NL, Karkada M, Liwski RS, Mansour M. Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response. OncoImmunology. November, 2014 https://www.ncbi.nlm.nih.gov/pubmed/25960932

Karkada M, Berinstein NL, Mansour M. Therapeutic vaccines and cancer: focus on DPX-0907. Biologics: Targets and Therapy. February, 2014 https://www.ncbi.nlm.nih.gov/pubmed/24596453

Karkada M, Quinton T, Blackman R, Mansour M. Tumor inhibition by DepoVax-based cancer vaccine is accompanied by reduced regulatory/suppressor cell proliferation and tumor infiltration. ISRN Oncology. March, 2013 https://www.ncbi.nlm.nih.gov/pubmed/23533812

Berinstein NL, Karkada M, Morse MA, Nemunaitis JL, Chatta G, Kaufman H, Odunsi K, Nigam R, Sammatur L, MacDonald LD, Weir GM, Stanford MM, Mansour M. First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. J Trans Med. August, 2014 https://www.ncbi.nlm.nih.gov/pubmed/22862954

Weir GM, Liwski RS, Mansour M. Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccinations. Cancers. August, 2011 https://www.ncbi.nlm.nih.gov/pubmed/24212948

Karkada M, Weir GM, Quinton T, Fuentes-Ortega A, Mansour M. A liposome-based platform, VacciMax, and its modified water-free platform DepoVax enhance efficacy of in vivo nucleic acid delivery. Vaccine, August, 2010 https://www.ncbi.nlm.nih.gov/pubmed/20656034

Karkada M, Weir GM, Quinton T, Sammatur L, MacDonald LD, Grant A, Liwski R, Juskevicius R, Sinnathamby G, Philip R, Mansour M. A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses. J Immunother. April, 2010 https://www.ncbi.nlm.nih.gov/pubmed/20445345

Daftarian PM, Mansour M, Pohajdak B, Fuentes-Ortega A, Korets-Smith E, MacDonald L, Weir G, Brown RG, Kast WM. Rejection of large HPV-16 expressing tumors in aged mice by a single immunization of VacciMax® encapsulated CTL/T helper peptides. J Trans Med. June, 2007 https://www.ncbi.nlm.nih.gov/pubmed/17555571

Mansour M, Pohajdak B, Kast WM, Fuentes-Ortega A, Korets-Smith E, Weir GM, Brown RG, Daftarian P. Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax®. J Trans Med. April, 2007 https://www.ncbi.nlm.nih.gov/pubmed/17451606

Daftarian P, Mansour M, Benoit AC, Pohajdak B, Hoskin DW, Brown RG, Kast WM. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Vaccine, June, 2006 https://www.ncbi.nlm.nih.gov/pubmed/16675074

Tremblay ML, Davis C, Bowen CV, Stanley O, Parsons C, Weir G, Karkada M, Stanford MM, Brewer KD. Using MRI cell tracking to monitor immune cell recruitment in response to a peptide-based cancer vaccine. Magn Reson Med. July 2018 https://www.ncbi.nlm.nih.gov/pubmed/29193231

Brewer KD, Weir GM, Dude I, Davis C, Parsons C, Penwell A, Rajagopalan R, Sammatur L, Bowen CV, Stanford MM. Unique depot formed by an oil based vaccine facilitates active antigen uptake and provides effective tumour control. J Biomed Sci. January 2018 https://www.ncbi.nlm.nih.gov/pubmed/29374458

Brewer KD, DeBay DR, Dude I, Davis C, Lake K, Parsons C, Rajagopalan R, Weir G, Stanford MM, Mansour M, Bowen CV. Using lymph node swelling as a potential biomarker for successful vaccination. Oncotarget. June 2016 https://www.ncbi.nlm.nih.gov/pubmed/27232944

DeBay DR, Brewer KD, LeBlanc SA, Weir GM, Stanford MM, Mansour M, Bowen CV. Using MRI to evaluate and predict therapeutic success from depot-based cancer vaccines. Mol Ther Methods Clinical Development. December, 2015 https://www.ncbi.nlm.nih.gov/pubmed/26730395

Brewer KD, Lake K, Pelot N, Stanford MM, DeBay DR, Penwell A, Weir GM, Karkada M, Mansour M, Bowen CV. Clearance of depot vaccine SPIO-labeled antigen and substrate visualized using MRI. Vaccine. December, 2014 https://www.ncbi.nlm.nih.gov/pubmed/25444822

Penwell A, Sharp K, Mansour M, Sammatur L. Development and validation of an HPLC/UV assay for separation and quantification of peptide antigens from a liposomal vaccine delivery platform. J Pharmaceut Biomed. July, 2012 https://www.ncbi.nlm.nih.gov/pubmed/22516680

Karkada M, Weir GM, Quinton T, Fuentes-Ortega A, Mansour M. A liposome-based platform, VacciMax®, and its modified water-free platform DepoVaxTM enhance efficacy of in vivo nucleic acid delivery. Vaccine, August, 2010 https://www.ncbi.nlm.nih.gov/pubmed/20656034

Weir GM, MacDonald LD, Rajagopalan R, Sivko GS, Valderas MW, Rayner J, Berger BJ, Sammatur L, Stanford MM. Single dose of DPX-rPA, an enhanced-delivery anthrax vaccine formulation, protects against a lethal Bacillus anthracis spore inhalation challenge. npj Vaccines February 2019 https://www.nature.com/articles/s41541-019-0102-z

Langley JM, MacDonald LD, Weir GM, MacKinnon-Cameron D, Ye L, McNeil S, Schepens B, Saelens X, Stanford MM, Halperin SA. A Respiratory Syncytial Virus Vaccine Based on the Small Hydrophobic Protein Ectodomain Presented With a Novel Lipid-Based Formulation Is Highly Immunogenic and Safe in Adults: A First-in-Humans Study. J Infect Dis. July 2018 https://www.ncbi.nlm.nih.gov/pubmed/29617814

Weir GM, Karkada M, Hoskin D, Stanford MM, MacDonald L, Mansour M, Liwski RS. Combination of poly I:C and Pam3CSK4 enhances activation of B cells in vitro and boosts antibody responses to protein vaccines in vivo. PLoS One. June 2017 https://www.ncbi.nlm.nih.gov/pubmed/28662082

MacDonald LD, MacKay A, Kaliaperumal V, Weir G, Penwell A, Rajagopalan R, Langley JM, Halperin S, Mansour M, Stanford MM. Type III hypersensitivity reactions to a B cell epitope antigen are abrogated using a depot forming vaccine platform. Hum Vaccin Immunother. January 2018 https://www.ncbi.nlm.nih.gov/pubmed/28933663

MacDonald LD, Fuentes-Ortega A, Sammatur L, Mansour M. Efficacy of a single dose hepatitis B depot vaccine. Vaccine. October, 2010 https://www.ncbi.nlm.nih.gov/pubmed/20832491

Mansour M, Brown RG, Morris A, Smith B, Halperin SA. Improved efficacy of a licensed acellular pertussis vaccine, reformulated in an adjuvant emulsion of liposomes in oil, in a murine model. Clin Vaccine Immunol. October, 2007 https://www.ncbi.nlm.nih.gov/pubmed/17715327

Bechert U, Rohde J, Freer H, Wagner B. IgG4/7 responses correlate with contraception in mares vaccinated with SpayVac. Theriogenology. November 2018 https://www.ncbi.nlm.nih.gov/pubmed/30165305

Bechert U, Fraker MA. Immune response of African elephants to a single dose of SpayVac®, a pZP contraceptive vaccine, over a seven year period. Pachyderm. July, 2016

Mask TA, Schoenecker KA, Kane AJ, Ransom JI, Bruemmer JE. Serum antibody immunoreactivity to equine zona protein after SpayVac vaccination. Theriogenology, July, 2015. https://www.ncbi.nlm.nih.gov/pubmed/25922172

Bechert U, Bartell J, Kutzler M, Menino A, Bildfell R, Anderson M, Fraker M. Effects of two porcine zona pellucid immunocontraceptive vaccines on ovarian activity in horses. J Wildlife Manage. July, 2013 https://wildlife.onlinelibrary.wiley.com/doi/10.1002/jwmg.600

Locke SL, Cook MW, Harveson LA, Davis DS, Lopez RR, Silvy NJ, Fraker MA. Effectiveness of Spayvac® for reducing white-tailed deer fertility. J Wildlife Dis. October, 2007 https://www.ncbi.nlm.nih.gov/pubmed/17984269

Levy JK, Mansour M, Crawford PC, Pohajdak P, Brown RG. Survey of zona pellucida antigens for immunocontraception of cats. Theriogenology, March, 2005 https://www.ncbi.nlm.nih.gov/pubmed/15725441

Gorman SP, Levy JK, Hampton AL, Collante WR, Harris AL, Brown RG. Evaluation of a porcine zona pellucida vaccine for the immunocontraception of domestic kittens (Felis catus). Theriogenology, July 2002. https://www.ncbi.nlm.nih.gov/pubmed/12182357

Fraker MA, Brown RG, Gaunt GE, Kerr JA, Pohajdak B. Long-lasting, single-dose immunocontraception of feral fallow deer in British Columbia. J Wildlife Manage. May, 2002

Brown RG, Bowen WD, Eddington JD, Kimmins WC, Mezei M, Parsons JL, Pohajdak B. Temporal trends in antibody production in captive grey, harp and hooded seals to a single administration immunocontraceptive vaccine. J Reprod Immunol. August, 1997 https://www.ncbi.nlm.nih.gov/pubmed/9373858

Brown RG, Bowen WD, Eddington JD, Kimmins WC, Mezei M, Parsons JL, Pohajdak B. Evidence for a long-lasting single administration contraceptive vaccine in wild grey seals. J Reprod Immunol. August, 1997 https://www.ncbi.nlm.nih.gov/pubmed/9373857

Brown RG, Kimmins WC, Mezei M, Parsons J, Pohajdak B, Bowen WD. Birth control for grey seals. Nature. January, 1996

High Standards. Even Higher Aspirations.

Working at IMV brings you to the forefront of cutting-edge science and research for cancer and other serious diseases. We’ve worked hard to build a culture of innovation and collaboration.

Learn more about life at IMV